The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
The biosimilar Ustekinumab has been developed and manufactured by the company
Granules India received approval from Brazilian Health Regulatory Agency ANVISA
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Subscribe To Our Newsletter & Stay Updated
